Business Context and Reporting Period
Company: RedHill Biopharma Ltd. (Nasdaq: RDHL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 18, 2026
Reporting Period: Current event announcement for June 2026.
Business Overview: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases, infectious diseases, and oncology. Its primary commercial product is Talicia (for H. pylori infection), co-commercialized with Cumberland Pharmaceuticals. Key pipeline assets include opaganib, RHB-102 (Bekinda), RHB-204, and RHB-107.
Key Financial Metrics
Capital Raise (Private Placement):
- Upfront Gross Proceeds: Approximately $6.0 million.
- Potential Additional Proceeds: Up to approximately $13.4 million upon full exercise of warrants.
- Total Potential Gross Proceeds: Up to $19.4 million.
- Securities Issued: 8,571,429 American Depositary Shares (ADSs) plus Series A-1 and Series A-2 warrants (each covering 8,571,429 ADSs).
- Purchase Price: $0.70 per ADS (combined with warrants).
- Warrant Terms:
- Series A-1: Exercise price $0.86/ADS, 5-year term, immediately exercisable.
- Series A-2: Exercise price $0.70/ADS, 18-month term, immediately exercisable.
Other Financial Data: The filing text does not provide specific values for revenue, net profit, operating cash flow, gross margins, total debt, or current liquidity positions as of the reporting date. The document focuses exclusively on the terms of the private placement.
Material Changes and Use of Proceeds
Material Change: The Company has entered a definitive agreement for a private placement to raise capital, representing a significant change in its equity structure and cash position upon closing (expected June 22, 2026).
Use of Proceeds:
- Support a potential strategic product acquisition (no definitive agreement executed yet).
- Working capital.
- Research and development (R&D).
- General corporate purposes.
Guidance, Outlook, and Risks
Management Commentary: Management intends to use the capital to advance its pipeline and potentially acquire strategic products. The Company highlights ongoing development programs for opaganib (Ebola, radiation exposure, prostate cancer), RHB-102 (GI intolerance, gastroenteritis, IBS-D), RHB-204 (Crohn's disease), and RHB-107 (pandemic preparedness).
Key Risks and Contingencies:
- Warrant Exercise: No assurance that warrants will be exercised or that the Company will receive the potential $13.4 million in additional proceeds.
- Acquisition Uncertainty: No definitive acquisition agreement has been executed; any transaction is subject to customary conditions.
- Regulatory Risks: Risks regarding FDA/EMA approvals for Talicia, opaganib, RHB-102, and RHB-204.
- Legal Risks: Uncertainty regarding the enforcement of a judgment against Kukbo and recovery of awarded amounts.
- Listing Compliance: Risk of failing to maintain Nasdaq listing requirements, including minimum bid price.
- Funding Risks: Uncertainty regarding continued U.S. government R&D funding support.
Investor Verification Checklist
- Verify the closing date of the private placement (expected June 22, 2026) and confirmation of the $6.0 million upfront receipt.
- Monitor the status of the potential strategic product acquisition to determine if a definitive agreement is executed.
- Track the exercise activity of the Series A-1 and Series A-2 warrants to assess the realization of the potential $13.4 million in proceeds.
- Review upcoming regulatory milestones for Talicia (UK submission), opaganib (Priority Review Voucher status), and RHB-102 (Phase 2 proof-of-concept).
- Assess the Company's cash runway post-closing relative to its R&D burn rate and potential acquisition costs.
- Confirm the Company's compliance status with Nasdaq listing requirements, specifically the minimum bid price.